Ulcerative Colitis (UC) is a chronic inflammatory disease that can extend throughout the entire colon. The inflammation, which can range from mild to severe, affects the inner lining of the colon and may lead to a variety of disabling physiological symptoms as well as psychological issues. As a lifelong relapsing, remitting disease, there is an unmet need for safe and effective new treatments that not only induce remission, but also maintain the disease in a state of remission.
Current UC therapies seek to suppress inappropriate inflammatory responses, heal the inner lining of the colon and improve overall patient quality of life. Traditional small molecule therapies for UC include aminosalicylates (oral and rectal), glucocorticosteroids (oral, rectal and injected), and immunomodulators (oral). More recently, a number of biologics in the form of monoclonal antibodies have also been approved.
The efficacy of existing therapies varies according to the patient and disease status. All treatment options have at least one limitation in terms of initial patient response, persistence of response, adverse events, routes of administration or cost. Patients that do not respond well to therapy may require surgery to remove of the diseased portion of the colon.
Sublimity is advancing development of ST-0529 with hopes of offering patients a safe, efficacious, cost-effective treatment option to reduce, delay or eliminate the need for biologics and to obviate the need for steroids.
It’s important not to confuse an inflammatory bowel disease (IBD) like ulcerative colitis with irritable bowel syndrome (IBS). IBS is a disorder that affects the muscle contractions of the bowel and is not characterized by intestinal inflammation, nor is it a chronic disease.